LM Diagnostic Assay

by | May 15, 2024 | LM

“Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern...

AANS Follow-Up

by | May 10, 2024 | Uncategorized

Thank you to everyone who stopped by our booth at the AANS annual meeting to learn more about our ReSPECT Recurrent Glioblastoma and Leptomeningeal Metastases clinical trials! If you missed us and would like more information, you can send us an email at...

LM Acquistition Meeting

by | May 9, 2024 | LM

Plus Therapeutics provided highlights regarding Leptomeningeal Metastases acquisition and topline clinical trial data on the FORESEE Trial on this morning’s investor call. Listen to the Replay: https://edge.media-server.com/mmc/p/nor9kmxs/ Highlights:...

Musella GBM Patient Webinar

by | May 6, 2024 | GBM

➡️ GLIOBLASTOMA PATIENT WEBINAR ⬅️ Join us as the @MusellaFoundation hosts Dr. Andrew Brenner and Dr. Marc Hedrick in a discussion about the ReSPECT-GBM Phase 2 Clinical Trial for Recurrent Glioblastoma. The webinar will take place May 20 2pm EST with a recording to...

Reminder: AANS 2024

by | May 3, 2024 | Uncategorized

Reminder to come stop by the Plus Therapeutics booth #1057 at the American Association of Neurological Surgeons (AANS) annual conference this weekend in Chicago! Our team will be in the exhibit hall during the entire conference, so come say hello 👋 Home #AANS2024...